ArticleCancer medicine2023
Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Effectiveness and Safety of PD-1 Inhibitor Rechallenge After Prior Immunotherapy in Patients Aged ≥ 60 Years with Advanced Non-Small-Cell Lung Cancer: A Single-Center Retrospective Study.Drugs - real world outcomes · 2026Article
- Trends and current status in anticancer therapy for older patients with non-small cell lung cancer in Japan, 2016-2021.International journal of clinical oncology · 2026Article
- Using the COM-B framework to elucidate facilitators and barriers of home-based pulmonary rehabilitation adherence among elderly lung cancer survivors in China: a qualitative study.BMC geriatrics · 2026Article
- Safety and efficacy of PRaG therapy in elderly cancer patients.Immunotherapy advances · 2026Article
- Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.Oncoimmunology · 2025Observational
- Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Prognostic factors affecting mortality in elderly, low body mass index, and poor performance status groups with lung cancer: analysis of the 2016 Korean Association of Lung Cancer Registry (KALC-R) database.Translational lung cancer research · 2025Article
- Article
- Clinical features of immune checkpoint inhibitor-related pneumonitis in older patients with lung cancer receiving immune checkpoint inhibitors-based therapy: a retrospective study.BMC geriatrics · 2025Article
- Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- The Impact of Immune-Related Adverse Event Severity on Prognosis in Elderly Patients With Nonsmall-Cell Lung Cancer in First-Line Immune Checkpoint Inhibitor Treatment.Thoracic cancer · 2025Article
- Safety and efficacy of transbronchial cryobiopsy for elderly lung cancer patients.BMC pulmonary medicine · 2024Article
- Article
- Article
- Safety of flexible bronchoscopy and clinical course for elderly patients with suspected primary lung cancer.Thoracic cancer · 2024Article
- Real-world treatment patterns, biomarker testing, and clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era.Frontiers in oncology · 2024Article
- Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer.Frontiers in oncology · 2024Review
- The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review.Translational lung cancer research · 2023Review
- Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.Cancer medicine · 2023Article
- Prognostic Impact of Sarcopenia on Clinical Outcomes in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmune-checkpoint inhibitors (ICIs) are effective against advanced non-small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is unclear. This study was designed to address this question.
methodsWe enrolled patients who received ICI monotherapy in Japan between December 2015 and December 2017; those ≥75 years of age comprised the elderly group. We compared the efficacy and safety of ICI monotherapy in elderly patients with those in younger patients and explored prognostic factors in elderly patients.
resultsWe enrolled 676 patients; 137 (20.3%) were assigned to the elderly group. The median age of the elderly and younger groups was 78 (range, 75-85) and 66 (range, 34-74) years. The median progression-free survival (4.8 months vs. 3.3 months, p = 0.1589) and median overall survival (12.3 months vs. 13.0 months, p = 0.5587) were similar between the elderly and younger groups. Multivariate analysis revealed that a significantly better OS in the elderly group was associated with better responses to first- or second-line ICI treatment (p = 0.011) and more immune-related adverse events (irAEs) (p = 0.02). IrAEs that led to ICI discontinuation occurred in 34 of 137 patients (24.8%) in the elderly group, and their survival was significantly higher than that in those who did not have irAEs.
conclusionICI is also effective in elderly NSCLC patients, and treatment discontinuation due to irAEs may be a good prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.